表紙:がんバイオマーカー市場- バイオマーカータイプ別、がんタイプ別、主要地域別:業界動向と世界の予測
市場調査レポート
商品コード
1471917

がんバイオマーカー市場- バイオマーカータイプ別、がんタイプ別、主要地域別:業界動向と世界の予測

Cancer Biomarkers Market - Distribution by Type of Biomarker, Type of Cancer and Key Geographical Regions : Industry Trends and Global Forecasts

出版日: | 発行: Roots Analysis | ページ情報: 英文 309 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.74円
がんバイオマーカー市場- バイオマーカータイプ別、がんタイプ別、主要地域別:業界動向と世界の予測
出版日: 2024年04月16日
発行: Roots Analysis
ページ情報: 英文 309 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

がんバイオマーカーの市場規模は、2024年に286億米ドルになるとみられ、2024年~2035年の予測期間中のCAGRは5%になると予測されています。

ヘルスケア業界では、過去数十年にわたり、さまざまな標的療法、免疫療法、抗がんワクチンの導入より、がん治療の選択肢が大きく進化してきました。しかし、臨床がん研究は、高い失敗率、薬剤・治療の限界、致命的な副作用の可能性など、依然として大きな課題に直面しています。同じ病期、同じ種類のがんであっても、患者の分子プロファイルが異なるため、推奨される治療法に対する反応も異なるからです。この懸念に対処するため、製薬開発者とヘルスケア専門家は、腫瘍精密医療として知られる個別化アプローチを採用しています。このアプローチでは、分子マーカーを同定し、その特徴を明らかにすることが必要であり、その多くは重要な治療方針を決定するために使用することが検証されています。

PD-L1、BRAF、EGFRのような単一分析値のバイオマーカーは、複数のがんの適応症において確立された役割を果たしてきたが、個々のゲノム構造の微妙な違いのために、患者の反応を決定するには、これらのバイオマーカーのみの使用では不十分であることが証明されています。バイオテクノロジーの進歩はハイスループット・ツールの開発を促進し、ゲノム/エクソーム・プロファイルに基づくより優れたバイオマーカーの確立を可能にしました。腫瘍変異負荷(TMB)、マイクロサテライト不安定性(MSI)/ミスマッチ修復(MMR)欠損、腫瘍浸潤リンパ球(TIL)、一塩基変異(SNV)、コピー数変異(CNV)などの新規バイオマーカーが、現在多くの臨床研究において研究されています。

当レポートでは、世界がんバイオマーカー市場について調査し、市場の概要とともに、バイオマーカータイプ別、がんタイプ別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

第2章 調査手法

第3章 経済およびその他のプロジェクト特有の考慮事項

第4章 エグゼクティブサマリー

第5章 イントロダクション

  • 章の概要
  • がんバイオマーカーの概要
  • がんバイオマーカーの種類
  • 新しいがんバイオマーカー
  • 将来の展望

第6章 市場情勢

  • 章の概要
  • がんバイオマーカー検査ソリューション:市場情勢
  • がんバイオマーカー検査ソリューション:開発者の情勢

第7章 製品競合分析

第8章 企業プロファイル

第9章 バイオマーカーに基づく臨床試験のための革新的な研究デザイン

第10章 臨床試験の分析

  • 章の概要
  • 範囲と調査手法
  • がんバイオマーカー:臨床試験分析

第11章 出版物の分析

第12章 大手製薬企業:ベンチマーク分析

第13章 ケーススタディ:コンパニオン診断業界におけるバリューチェーンの分析

第14章 将来の成長機会

第15章 世界のがんバイオマーカー市場

第16章 がんバイオマーカー市場、バイオマーカータイプ別

第17章 がんバイオマーカー市場、がんタイプ別

第18章 がんバイオマーカー市場、主要地域別

第19章 結論

第20章 エグゼクティブインサイト

第21章 付録1:表形式のデータ

第22章 付録2:企業・団体一覧

図表

List of Tables

  • Table 6.1 Cancer Biomarkers Testing Solutions: Information on Type of Biomarkers
  • Table 6.2 Cancer Biomarkers Testing Solutions: Information on Profiling Technologies and Analytical Technique
  • Table 6.3 Cancer Biomarkers Testing Solutions: Information on Turnaround Time, Sample Input and Type of Nucleic Acid Tested
  • Table 6.4 Cancer Biomarkers Testing Solutions: Information on Type of Cancer
  • Table 6.5 Cancer Biomarkers Testing Solutions: Information on Application Area and End Users
  • Table 6.6 List of Cancer Biomarker Testing Solution Providers
  • Table 8.1 Cancer Biomarkers Testing Solution Providers: List of Companies Profiled
  • Table 8.2 Agilent: Company Overview
  • Table 8.3 Agilent: Cancer Biomarkers Testing Solutions Portfolio
  • Table 8.4 Agilent: Recent Developments and Future Outlook
  • Table 8.5 ARUP Laboratories: Company Overview
  • Table 8.6 ARUP Laboratories: Cancer Biomarker Testing Solutions Portfolio
  • Table 8.7 ARUP Laboratories: Recent Developments and Future Outlook
  • Table 8.8 BioReference: Company Overview
  • Table 8.9 BioReference: Cancer Biomarker Testing Solutions Portfolio
  • Table 8.10 BioReference: Recent Developments and Future Outlook
  • Table 8.11 Foundation Medicine: Company Overview
  • Table 8.12 Foundation Medicine: Cancer Biomarker Testing Solutions Portfolio
  • Table 8.13 Foundation Medicine: Recent Developments and Future Outlook
  • Table 8.14 OncoDNA: Company Overview
  • Table 8.15 OncoDNA: Cancer Biomarker Testing Solutions Portfolio
  • Table 8.16 OncoDNA: Recent Developments and Future Outlook
  • Table 8.17 Q2 Solutions: Company Overview
  • Table 8.18 Q2 Solutions: Cancer Biomarker Testing Solutions Portfolio
  • Table 8.19 Q2 Solutions: Recent Developments and Future Outlook
  • Table 8.20 Thermo Fisher Scientific: Company Overview
  • Table 8.21 Thermo Fisher Scientific: Cancer Biomarker Testing Solutions Portfolio
  • Table 8.22 Thermo Fisher Scientific: Recent Developments and Future Outlook
  • Table 8.23 YuceBio: Company Overview
  • Table 8.24 YuceBio: Cancer Biomarker Testing Solutions Portfolio
  • Table 8.25 Asper Biogene: Company Overview
  • Table 8.26 Asper Biogene: Cancer Biomarkers Testing Solutions Portfolio
  • Table 8.27 Caris Life Sciences: Company Overview
  • Table 8.28 Caris Life Sciences: Cancer Biomarkers Testing Solutions Portfolio
  • Table 8.29 CeGaT: Company Overview
  • Table 8.30 CeGaT: Cancer Biomarkers Testing Solutions Portfolio
  • Table 8.31 Genekor Medical: Company Overview
  • Table 8.32 Genekor Medical: Cancer Biomarkers Testing Solutions Portfolio
  • Table 8.33 Guardant Health: Company Overview
  • Table 8.34 Guardant Health: Cancer Biomarkers Testing Solutions Portfolio
  • Table 8.35 Labcorp: Company Overview
  • Table 8.36 Labcorp: Cancer Biomarkers Testing Solutions Portfolio
  • Table 8.37 MedGenome: Company Overview
  • Table 8.38 MedGenome: Cancer Biomarkers Testing Solutions Portfolio
  • Table 8.39 NeoGenomics Laboratories: Company Overview
  • Table 8.40 NeoGenomics Laboratories: Cancer Biomarkers Testing Solutions Portfolio
  • Table 8.41 Nonacus: Company Overview
  • Table 8.42 Nonacus: Cancer Biomarkers Testing Solutions Portfolio
  • Table 8.43 Oxford Gene Technology: Company Overview
  • Table 8.44 Oxford Gene Technology: Cancer Biomarkers Testing Solutions Portfolio
  • Table 8.45 Personal Genome Diagnostics: Company Overview
  • Table 8.46 Personal Genome Diagnostics: Cancer Biomarkers Testing Solutions Portfolio
  • Table 8.47 PhenoPath: Company Overview
  • Table 8.48 PhenoPath: Cancer Biomarkers Testing Solutions Portfolio
  • Table 8.49 Positive Biosciences: Company Overview
  • Table 8.50 Positive Biosciences: Cancer Biomarkers Testing Solutions Portfolio
  • Table 8.51 Quest Diagnostics: Company Overview
  • Table 8.52 Quest Diagnostics: Cancer Biomarkers Testing Solutions Portfolio
  • Table 8.53 Tempus: Company Overview
  • Table 8.54 Tempus: Cancer Biomarkers Testing Solutions Portfolio
  • Table 20.1 Cell IDx: Company Snapshot
  • Table 20.2 CeGat: Company Snapshot
  • Table 20.3 NeoGenomics Laboratories: Company Snapshot
  • Table 21.1 Cancer Biomarker Testing Solutions: Distribution by Type of Biomarker
  • Table 21.2 Cancer Biomarker Testing Solutions: Distribution by Profiling Technology Used
  • Table 21.3 Cancer Biomarker Testing Solutions: Distribution by Analytical Technique Used
  • Table 21.4 Cancer Biomarker Testing Solutions: Distribution by Turnaround Time
  • Table 21.5 Cancer Biomarker Testing Solutions: Distribution by Sample Input
  • Table 21.6 Cancer Biomarker Testing Solutions: Distribution by Type of Nucleic Acid Tested
  • Table 21.7 Cancer Biomarker Testing Solutions: Distribution by Type of Cancer
  • Table 21.8 Cancer Biomarker Testing Solutions: Distribution by Application Area
  • Table 21.9 Cancer Biomarker Testing Solution Providers: Distribution by Year of Establishment
  • Table 21.10 Cancer Biomarker Testing Solution Providers: Distribution by Company Size
  • Table 21.11 Cancer Biomarker Testing Solution Providers: Distribution by Location of Headquarters (Region)
  • Table 21.12 Agilent: Annual Revenues, FY 2019-FY 2023 (USD Million)
  • Table 21.13 Thermo Fisher Scientific: Annual Revenues, FY 2019-FY 2023 (USD Million)
  • Table 21.14 Clinical Trial Analysis: Distribution by Trial Registration Year, 2019-2023
  • Table 21.15 Clinical Trial Analysis: Distribution by Trial Status
  • Table 21.16 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, 2019-2023
  • Table 21.17 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 21.18 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, 2019-2023
  • Table 21.19 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, 2019-2023
  • Table 21.20 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
  • Table 21.21 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 21.22 Clinical Trial Analysis: Distribution by Study Design
  • Table 21.23 Clinical Trial Analysis: Distribution by Type of Cancer
  • Table 21.24 Most Active Players: Distribution by Number of Registered Trials
  • Table 21.25 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
  • Table 21.26 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
  • Table 21.27 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
  • Table 21.28 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
  • Table 21.29 Publication Analysis: Cumulative Year-wise Trend of Publications, 2019-2023
  • Table 21.30 Publication Analysis: Distribution by Type of Publication
  • Table 21.31 Publication Analysis: Distribution by Type of Cancer
  • Table 21.32 Most Popular Copyright Holders: Distribution by Number of Publications
  • Table 21.33 Most Active Publishers: Distribution by Number of Publications
  • Table 21.34 Key Journals: Distribution by Number of Publications
  • Table 21.35 Key Journals: Distribution by Impact Factor
  • Table 21.36 Benchmarking Analysis: Big Pharma players
  • Table 21.37 Global Cancer Biomarkers Market, Historical Trends (2018-2023) (USD Billion)
  • Table 21.38 Global Cancer Biomarkers Market, Forecasted Estimates (2024-2035) Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.39 Cancer Biomarkers Market: Distribution by Type of Biomarker, 2018, 2024 and 2035 (USD Billion)
  • Table 21.40 Cancer Biomarkers Market for HER2 Biomarkers: Historical Trends (2018-2023) (USD Billion)
  • Table 21.41 Cancer Biomarkers Market for HER2 Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.42 Cancer Biomarkers Market for MET Biomarkers: Historical Trends (2018-2023) (USD Billion)
  • Table 21.43 Cancer Biomarkers Market for MET Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.44 Cancer Biomarkers Market for EGFR Biomarkers: Historical Trends (2018-2023) (USD Billion)
  • Table 21.45 Cancer Biomarkers Market for EGFR Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.46 Cancer Biomarkers Market for PD-L1 Biomarkers: Historical Trends (2018-2023) (USD Billion)
  • Table 21.47 Cancer Biomarkers Market for PD-L1 Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.48 Cancer Biomarkers Market for NTRK Biomarkers: Historical Trends (2018-2023) (USD Billion)
  • Table 21.49 Cancer Biomarkers Market for NTRK Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.50 Cancer Biomarkers Market for ALK Biomarkers: Historical Trends (2018-2023) (USD Billion)
  • Table 21.51 Cancer Biomarkers Market for ALK Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.52 Cancer Biomarkers Market for Other Biomarkers: Historical Trends (2018-2023) (USD Billion)
  • Table 21.53 Cancer Biomarkers Market for Other Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.54 Cancer Biomarkers Market: Distribution of Novel Biomarkers, 2018, 2024 and 2035 (USD Billion)
  • Table 21.55 Cancer Biomarkers Market for SNV Biomarkers: Historical Trends (2018-2023) (USD Billion)
  • Table 21.56 Cancer Biomarkers Market for SNV Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.57 Cancer Biomarkers Market for MSI Biomarkers: Historical Trends (2018-2023) (USD Billion)
  • Table 21.58 Cancer Biomarkers Market for MSI Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.59 Cancer Biomarkers Market for CNV Biomarkers: Historical Trends (2018-2023) (USD Billion)
  • Table 21.60 Cancer Biomarkers Market for CNV Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.61 Cancer Biomarkers Market for TMB Biomarkers: Historical Trends (2018-2023) (USD Billion)
  • Table 21.62 Cancer Biomarkers Market for TMB Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.63 Cancer Biomarkers Market for TIL Biomarkers: Historical Trends (2018-2023) (USD Billion)
  • Table 21.64 Cancer Biomarkers Market for TIL Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.65 Cancer Biomarkers Market: Distribution by Type of Cancer, 2018, 2024 and 2035 (USD Billion)
  • Table 21.66 Cancer Biomarkers Market for Breast Cancer: Historical Trends (2018-2023) (USD Billion)
  • Table 21.67 Cancer Biomarkers Market for Breast Cancer: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.68 Cancer Biomarkers Market for Prostate Cancer: Historical Trends (2018-2023) (USD Billion)
  • Table 21.69 Cancer Biomarkers Market for Prostate Cancer: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.70 Cancer Biomarkers Market for Colorectum Cancer: Historical Trends (2018-2023) (USD Billion)
  • Table 21.71 Cancer Biomarkers Market for Colorectum Cancer: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.72 Cancer Biomarkers Market for Lung Cancer: Historical Trends (2018-2023) (USD Billion)
  • Table 21.73 Cancer Biomarkers Market for Lung Cancer: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.74 Cancer Biomarkers Market for Thyroid Cancer: Historical Trends (2018-2023) (USD Billion)
  • Table 21.75 Cancer Biomarkers Market for Thyroid Cancer: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.76 Cancer Biomarkers Market for Bladder Cancer: Historical Trends (2018-2023) (USD Billion)
  • Table 21.77 Cancer Biomarkers Market for Bladder Cancer: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.78 Cancer Biomarkers Market for Melanoma: Historical Trends (2018-2023) (USD Billion)
  • Table 21.79 Cancer Biomarkers Market for Melanoma: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.80 Cancer Biomarkers Market for Non-Hodgkin Lymphoma: Historical Trends (2018-2023) (USD Billion)
  • Table 21.81 Cancer Biomarkers Market for Non-Hodgkin Lymphoma: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.82 Cancer Biomarkers Market for Endometrial Cancer: Historical Trends (2018-2023) (USD Billion)
  • Table 21.83 Cancer Biomarkers Market for Endometrial Cancer: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.84 Cancer Biomarkers Market for Kidney Cancer: Historical Trends (2018-2023) (USD Billion)
  • Table 21.85 Cancer Biomarkers Market for Kidney Cancer: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.86 Cancer Biomarkers Market for Leukemia: Historical Trends (2018-2023) (USD Billion)
  • Table 21.87 Cancer Biomarkers Market for Leukemia: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.88 Cancer Biomarkers Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035 (USD Billion)
  • Table 21.89 Cancer Biomarkers Market in North America: Historical Trends (2018-2023) (USD Billion)
  • Table 21.90 Cancer Biomarkers Market in North America: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.91 Cancer Biomarkers Market in the US: Historical Trends (2018-2023) (USD Billion)
  • Table 21.92 Cancer Biomarkers Market in the US: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.93 Cancer Biomarkers Market in Canada: Historical Trends (2018-2023) (USD Billion)
  • Table 21.94 Cancer Biomarkers Market in Canada: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.95 Cancer Biomarkers Market in Europe: Historical Trends (2018-2023) (USD Billion)
  • Table 21.96 Cancer Biomarkers Market in Europe: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.97 Cancer Biomarkers Market in the UK: Historical Trends (2018-2023) (USD Billion)
  • Table 21.98 Cancer Biomarkers Market in the UK: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.99 Cancer Biomarkers Market in Germany: Historical Trends (2018-2023) (USD Billion)
  • Table 21.100 Cancer Biomarkers Market in Germany: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.101 Cancer Biomarkers Market in France: Historical Trends (2018-2023) (USD Billion)
  • Table 21.102 Cancer Biomarkers Market in France: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.103 Cancer Biomarkers Market in Spain: Historical Trends (2018-2023) (USD Billion)
  • Table 21.104 Cancer Biomarkers Market in Spain: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.105 Cancer Biomarkers Market in Italy: Historical Trends (2018-2023) (USD Billion)
  • Table 21.106 Cancer Biomarkers Market in Italy: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.107 Cancer Biomarkers Market in Asia-Pacific: Historical Trends (2018-2023) (USD Billion)
  • Table 21.108 Cancer Biomarkers Market in Asia-Pacific: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.109 Cancer Biomarkers Market in China: Historical Trends (2018-2023) (USD Billion)
  • Table 21.110 Cancer Biomarkers Market in China: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.111 Cancer Biomarkers Market in Japan: Historical Trends (2018-2023) (USD Billion)
  • Table 21.112 Cancer Biomarkers Market in Japan: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.113 Cancer Biomarkers Market in India: Historical Trends (2018-2023) (USD Billion)
  • Table 21.114 Cancer Biomarkers Market in India: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.115 Cancer Biomarkers Market in Australia: Historical Trends (2018-2023) (USD Billion)
  • Table 21.116 Cancer Biomarkers Market in Australia: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.117 Cancer Biomarkers Market in South Korea: Historical Trends (2018-2023) (USD Billion)
  • Table 21.118 Cancer Biomarkers Market in South Korea: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.119 Cancer Biomarkers Market in New Zealand: Historical Trends (2018-2023) (USD Billion)
  • Table 21.120 Cancer Biomarkers Market in New Zealand: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.121 Cancer Biomarkers Market in Rest of the World: Historical Trends (2018-2023) (USD Billion)
  • Table 21.122 Cancer Biomarkers Market in Rest of the World: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.123 Cancer Biomarkers Market in Brazil: Historical Trends (2018-2023) (USD Billion)
  • Table 21.124 Cancer Biomarkers Market in Brazil: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.125 Cancer Biomarkers Market in Argentina: Historical Trends (2018-2023) (USD Billion)
  • Table 21.126 Cancer Biomarkers Market in Argentina: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.127 Cancer Biomarkers Market in Chile: Historical Trends (2018-2023) (USD Billion)
  • Table 21.128 Cancer Biomarkers Market in Chile: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 21.129 Cancer Biomarkers Market in Egypt: Historical Trends (2018-2023) (USD Billion)
  • Table 21.130 Cancer Biomarkers Market in Egypt: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Forecast Methodology
  • Figure 2.3 Research Methodology: Robust Quality Control
  • Figure 2.4 Research Methodology: Key Market Segmentation
  • Figure 3.1 Lessons Learnt from Past Recessions
  • Figure 4.1 Executive Summary: Current Market Landscape (I/II)
  • Figure 4.2 Executive Summary: Current Market Landscape (II/II)
  • Figure 4.3 Executive Summary: Clinical Trial Analysis
  • Figure 4.4 Executive Summary: Publication Analysis
  • Figure 4.5 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 6.1 Cancer Biomarker Testing Solutions: Distribution by Type of Biomarker
  • Figure 6.2 Cancer Biomarker Testing Solutions: Distribution by Profiling Technology Used
  • Figure 6.3 Cancer Biomarker Testing Solutions: Distribution by Analytical Technique Used
  • Figure 6.4 Cancer Biomarker Testing Solutions: Distribution by Turnaround Time
  • Figure 6.5 Cancer Biomarker Testing Solutions: Distribution by Sample Input
  • Figure 6.6 Cancer Biomarker Testing Solutions: Distribution by Type of Nucleic Acid Tested
  • Figure 6.7 Cancer Biomarker Testing Solutions: Distribution by Type of Cancer
  • Figure 6.8 Cancer Biomarker Testing Solutions: Distribution by Application Area
  • Figure 6.9 Cancer Biomarker Testing Solution Providers: Distribution by Year of Establishment
  • Figure 6.10 Cancer Biomarker Testing Solution Providers: Distribution by Company Size
  • Figure 6.11 Cancer Biomarker Testing Solution Providers: Distribution by Location of Headquarters (Region)
  • Figure 7.1 Product Competitiveness Analysis: Cancer Biomarker Testing Solutions Offered by Players based in North America
  • Figure 7.2 Product Competitiveness Analysis: Cancer Biomarker Testing Solutions Offered by Players based in Europe
  • Figure 7.3 Product Competitiveness Analysis: Cancer Biomarker Testing Solutions Offered by Players based in Asia-Pacific
  • Figure 8.1 Agilent: Annual Revenues, FY 2019-FY 2023 (USD Million)
  • Figure 8.2 Thermo Fisher Scientific: Annual Revenues, FY 2019-FY 2023 (USD Million)
  • Figure 9.1 Enrichment Clinical Trial Design: Steps Involved
  • Figure 9.2 All-Comers Clinical Trial Design: Steps Involved
  • Figure 9.3 Hybrid Clinical Trial Design: Steps Involved
  • Figure 9.4 Adaptive Clinical Trial Design: Steps Involved
  • Figure 10.1 Clinical Trial Analysis: Distribution by Trial Registration Year, 2019-2023
  • Figure 10.2 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 10.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, 2019-2023
  • Figure 10.4 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 10.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, 2019-2023
  • Figure 10.6 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, 2019-2023
  • Figure 10.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
  • Figure 10.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 10.9 Clinical Trial Analysis: Distribution by Study Design
  • Figure 10.10 Clinical Trial Analysis: Distribution by Type of Cancer
  • Figure 10.11 Most Active Players: Distribution by Number of Registered Trials
  • Figure 10.12 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
  • Figure 10.13 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
  • Figure 10.14 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
  • Figure 10.15 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
  • Figure 11.1 Publication Analysis: Cumulative Year-wise Trend of Publications, 2019-2023
  • Figure 11.2 Publication Analysis: Distribution by Type of Publication
  • Figure 11.3 Publication Analysis: Distribution by Type of Cancer
  • Figure 11.4 Most Popular Copyright Holders: Distribution by Number of Publications
  • Figure 11.5 Word Cloud Analysis: Emerging Focus Areas
  • Figure 11.6 Most Active Publishers: Distribution by Number of Publications
  • Figure 11.7 Key Journals: Distribution by Number of Publications
  • Figure 11.8 Key Journals: Distribution by Impact Factor
  • Figure 12.1 Spider Web Analysis: Abbott
  • Figure 12.2 Spider Web Analysis: AbbVie
  • Figure 12.3 Spider Web Analysis: Amgen
  • Figure 12.4 Spider Web Analysis: AstraZeneca
  • Figure 12.5 Spider Web Analysis: Bayer
  • Figure 12.6 Spider Web Analysis: Boehringer Ingelheim
  • Figure 12.7 Spider Web Analysis: Bristol-Myers Squib
  • Figure 12.8 Spider Web Analysis: Eli Lilly
  • Figure 12.9 Spider Web Analysis: Gilead
  • Figure 12.10 Spider Web Analysis: GlaxoSmithKline
  • Figure 12.11 Spider Web Analysis: Merck
  • Figure 12.12 Spider Web Analysis: Novartis
  • Figure 12.13 Spider Web Analysis: Pfizer
  • Figure 12.14 Spider Web Analysis: Roche
  • Figure 12.15 Spider Web Analysis: Sanofi
  • Figure 12.16 Benchmarking Analysis: Big Pharma players
  • Figure 13.1 Companion Diagnostics: Value Chain
  • Figure 13.2 Cost Distribution Across Value Chain
  • Figure 13.3 Costs Associated with Research and Product Development
  • Figure 13.4 Costs Associated with Manufacturing and Assembly
  • Figure 13.5 Costs Associated with Clinical Trials, FDA Approval and Other Administrative Tasks
  • Figure 13.6 Costs Associated with Payer Negotiation and KOL Engagement
  • Figure 13.7 Costs Associated with Marketing and Sales
  • Figure 14.1 Cancer Biomarkers Market: Future Growth Opportunities
  • Figure 15.1 Global Cancer Biomarkers Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 15.2 Global Cancer Biomarkers Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Billion)
  • Figure 15.3 Global Cancer Biomarkers Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Billion)
  • Figure 16.1 Cancer Biomarkers Market: Distribution by Type of Biomarker, 2018, 2024 and 2035
  • Figure 16.2 Cancer Biomarkers Market for HER2 Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 16.3 Cancer Biomarkers Market for MET Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 16.4 Cancer Biomarkers Market for EGFR Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 16.5 Cancer Biomarkers Market for PD-L1 Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 16.6 Cancer Biomarkers Market for NTRK Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 16.7 Cancer Biomarkers Market for ALK Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 16.8 Cancer Biomarkers Market for Other Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 16.9 Cancer Biomarkers Market: Distribution of Novel Biomarkers, 2018, 2024 and 2035
  • Figure 16.10 Cancer Biomarkers Market for SNV Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 16.12 Cancer Biomarkers Market for MSI Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 16.13 Cancer Biomarkers Market for CNV Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 16.14 Cancer Biomarkers Market for TMB Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 16.15 Cancer Biomarkers Market for TIL Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 17.1 Cancer Biomarkers Market: Distribution by Type of Cancer, 2018, 2024 and 2035
  • Figure 17.2 Cancer Biomarkers Market for Breast Cancer, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 17.3 Cancer Biomarkers Market for Prostate Cancer, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 17.4 Cancer Biomarkers Market for Colorectum Cancer, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 17.5 Cancer Biomarkers Market for Lung Cancer, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 17.6 Cancer Biomarkers Market for Thyroid Cancer, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 17.7 Cancer Biomarkers Market for Bladder Cancer, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 17.8 Cancer Biomarkers Market for Melanoma, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 17.9 Cancer Biomarkers Market for Non-Hodgkin Lymphoma, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 17.10 Cancer Biomarkers Market for Endometrial Cancer, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 17.11 Cancer Biomarkers Market for Kidney Cancer, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 17.12 Cancer Biomarkers Market for Leukemia, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 18.1 Cancer Biomarkers Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
  • Figure 18.2 Cancer Biomarkers Market in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 18.3 Cancer Biomarkers Market in the US, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 18.4 Cancer Biomarkers Market in Canada, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 18.5 Cancer Biomarkers Market in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 18.6 Cancer Biomarkers Market in the UK, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 18.7 Cancer Biomarkers Market in Germany, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 18.8 Cancer Biomarkers Market in France, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 18.9 Cancer Biomarkers Market in Spain, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 18.10 Cancer Biomarkers Market in Italy, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 18.11 Cancer Biomarkers Market in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 18.12 Cancer Biomarkers Market in China, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 18.13 Cancer Biomarkers Market in Japan, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 18.14 Cancer Biomarkers Market in India, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 18.15 Cancer Biomarkers Market in Australia, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 18.16 Cancer Biomarkers Market in South Korea, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 18.17 Cancer Biomarkers Market in New Zealand, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 18.18 Cancer Biomarkers Market in Rest of the World, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 18.19 Cancer Biomarkers Market in Brazil, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 18.20 Cancer Biomarkers Market in Argentina, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 18.21 Cancer Biomarkers Market in Chile, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 18.22 Cancer Biomarkers Market in Egypt, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 19.1 Concluding Remarks: Market Landscape
  • Figure 19.2 Concluding Remarks: Clinical Trial Analysis
  • Figure 19.3 Concluding Remarks: Publication Analysis
  • Figure 19.4 Concluding Remarks: Market Forecast and Opportunity Analysis
目次
Product Code: RA100492

The cancer biomarkers market is valued at USD 28.6 billion in 2024 growing at a CAGR of 5% during the forecast period 2024-2035.

The healthcare industry has witnessed a significant evolution in cancer treatment options over the past few decades, with the introduction of various targeted therapies, immunotherapies, and anti-cancer vaccines. However, clinical cancer research continues to face substantial challenges, including high failure rates, drug / therapy limitations, and potentially fatal adverse effects. A prominent concern revolves around determining the appropriate treatment option for a specific type of cancer, as patients with the same cancer stage and type may exhibit different molecular profiles, leading to varying responses to recommended treatments. To address this concern, pharmaceutical developers and healthcare professionals have adopted a personalized approach known as oncology precision medicine. This approach involves identifying and characterizing molecular markers, many of which have been validated for use in making crucial treatment decisions.

While single analyte biomarkers, such as PD-L1, BRAF, and EGFR, have played an established role across multiple cancer indications, their sole use has proven insufficient in determining patient responses due to subtle differences in individual genomic makeups. Advances in biotechnology have facilitated the development of high-throughput tools, enabling the establishment of better biomarkers based on genome/exome profiles. Novel biomarkers, including tumor mutation burden (TMB), microsatellite instability (MSI) / mismatch repair (MMR) deficiency, tumor-infiltrating lymphocytes (TILs), Single Nucleotide Variants (SNVs), Copy Number Variants (CNVs), and others, are currently being investigated across numerous clinical studies.

Several diagnostics companies have developed or are developing analytical tests for these biomarkers, aimed at assisting physicians in making personalized treatment decisions. Notably, many major pharmaceutical players have shown interest in this domain and have launched clinical research initiatives to investigate the relevance and applications of multiple novel biomarkers.

With the growing interest from established companies and startups alike, the cancer biomarker market is poised for robust growth at a healthy compound annual growth rate (CAGR) in the forecast period, driven by the need for personalized and precise cancer treatment strategies.

Key Market Segments

Type of Biomarker

HER2

MET

EGFR

PD-L1

NTRK

ALK

  • Novel Biomarkers
  • Other Biomarkers

Type of Cancer

  • Breast Cancer
  • Prostate Cancer
  • Colorectum Cancer
  • Lung Cancer
  • Thyroid Cancer
  • Bladder Cancer
  • Melanoma
  • Non-Hodgkins Lymphoma
  • Endometrial Cancer
  • Kidney Cancer
  • Leukemia

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Research Coverage:

  • The report studies the cancer biomarkers market based on type of biomarker, type of cancer, and key geographical regions
  • The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
  • The report forecasts the revenue of market segments with respect to four major regions
  • This comprehensive report provides an in-depth analysis of cancer biomarkers and the associated market landscape. It begins with a general overview of cancer biomarkers, highlighting their importance in the healthcare industry and detailing the different types of biomarkers and their identification methods. The report also delves into novel biomarkers, their variations, and measurement techniques.
  • The report then offers a detailed assessment of the overall market landscape for testing solutions for novel cancer biomarkers. It covers various relevant parameters, such as biomarker types (MSI/MMR, TMB, TILs, SNV, and CNV), profiling technologies (genomics, immunoassay, bioinformatics, cytogenetics, and others), analytical techniques (next-generation sequencing, PCR, immunohistochemistry, whole-exome sequencing, and others), turnaround time, sample inputs (FFPE tissue, blood, plasma, and other bodily fluids), nucleic acid types (DNA and RNA), cancer types (bladder, breast, CNS, colorectal, endometrial, gastrointestinal, hematologic, lung, melanoma, ovarian, prostate, and others), and application areas (research and development, diagnostics, prognostics, disease risk assessment, and others). Additionally, the report provides a detailed list of developers offering novel cancer biomarker testing solutions, along with an analysis based on factors such as year of establishment, company size, and headquarters location.
  • The report includes a product competitiveness analysis of novel cancer biomarker testing solutions, based on product versatility (number of biomarkers evaluated and cancers targeted) and competitiveness (number of profiling technologies, analytical techniques, sample inputs, and turnaround time). It also features elaborate profiles of prominent players in the cancer biomarkers market, including overviews, financial information, product portfolios, recent developments, and future outlooks.
  • Furthermore, the report explores innovative study designs involved in conducting biomarker-based clinical trials for oncological disorders, highlighting the structure, advantages, and challenges of each design. It also provides a comprehensive clinical trial analysis of completed, ongoing, and planned studies focused on assessing novel cancer biomarkers (TMB, MSI/MMR, SNV, CNV, and TILs), based on parameters such as trial year, status, phase, patient population, sponsor type, active players, study design, therapeutic area, and geographical regions.
  • The report includes a detailed publication analysis of over 630 articles published between 2019 and 2023, highlighting the key focus areas of ongoing research related to novel cancer biomarkers. It covers trends based on publication year, type, cancer type, copyright holders, emerging focus areas, active publishers, and key journals.
  • Additionally, the report features a benchmark analysis of various big pharma players engaged in the cancer biomarkers domain, comparing their initiatives based on multiple relevant parameters and providing a heat map representation of their distribution across various parameters.
  • The report also discusses the various steps involved in the production of companion diagnostics, including R&D, clinical assessment, manufacturing and assembly, payer negotiation, marketing activities, and cost distribution across these stages.
  • Furthermore, the report explores upcoming opportunities for cancer biomarker testing solution providers, such as the rise in biomarker-based oncology clinical trials, increasing focus on precision medicine, and the development of companion diagnostic products.
  • The report provides a detailed cancer biomarkers market forecast analysis, including estimates of the existing market size, market value, and future opportunity for cancer biomarker companies over the next 12 years (2024-2035). It offers detailed projections of the current and future market opportunity across different types of biomarkers (HER2, MET, EGFR, PD-L1, NTRK, ALK, novel biomarkers, and others), cancer types (breast, prostate, colorectal, lung, thyroid, bladder, melanoma, non-Hodgkin lymphoma, endometrial, kidney, and leukemia), and key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World).

Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the cancer biomarkers market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies

  • Agilent
  • ARUP Laboratories
  • BioReference
  • Foundation Medicine
  • OncoDNA
  • Q2 Solutions
  • Thermo Fisher Scientific
  • YuceBio
  • Asper Biogene
  • Caris Life Sciences
  • CeGaT
  • Genekor Medical
  • Guardant Health
  • Labcorp
  • MedGenome
  • NeoGenomics Laboratories
  • Nonacus
  • Oxford Gene Technology
  • Personal Genome Diagnostics
  • PhenoPath
  • Positive Biosciences
  • Quest Diagnostics
  • Tempus

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Market Share Insights
  • 1.3. Key Market Insights
  • 1.4. Research Coverage
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Future Estimates
    • 3.2.2. Currency Coverage and Foreign Exchange Rate
      • 3.2.2.1. Major Currencies Affecting the Market
      • 3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
      • 3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
      • 3.2.2.4. Strategies for Mitigating Foreign Exchange Risks
    • 3.2.3. Trade Policies
      • 3.2.3.1. Impact of Trade Barriers on the Market
      • 3.2.3.2. Strategies for Mitigating the Risks associated with Trade Barriers
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. An Overview of Cancer Biomarkers
    • 5.2.1. Need for Cancer Biomarkers
    • 5.2.2. Identification of a Candidate Biomarker
  • 5.3. Type of Cancer Biomarkers
  • 5.4. Novel Cancer Biomarkers
    • 5.4.1. Tumor Mutation Burden (TMB)
      • 5.4.1.1. Variation of TMB across Multiple Indications
      • 5.4.1.2. Methods for Measurement of TMB
      • 5.4.1.3. Factors Affecting Measurement of TMB
      • 5.4.1.4. Initiatives for Assessment of TMB as a Potential Biomarker
    • 5.4.2. Microsatellite Instability / Mismatch Repair Deficiency (MSI / MMR)
      • 5.4.2.1. Variation of MSI across Multiple Indications
      • 5.4.2.2. Methods for Measurement of MSI
    • 5.4.3. Single Nucleotide Variants
      • 5.4.3.1. Variation of SNV across Multiple Indications
      • 5.4.3.2. Methods for Measurement of SNV
    • 5.4.4. Copy Number Variants
      • 5.4.4.1. Variation of CNV across Multiple Indications
      • 5.4.4.2. Methods for Measurement of CNV
    • 5.4.5. Tumor Infiltrating Lymphocytes and Other Novel Biomarkers
  • 5.5. Future Perspective

6. MARKET LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. Cancer Biomarker Testing Solutions: Overall Market Landscape
    • 6.2.1. Analysis by Type of Biomarker
    • 6.2.2. Analysis by Profiling Technology Used
    • 6.2.3. Analysis by Analytical Technique Used
    • 6.2.4. Analysis by Turnaround Time
    • 6.2.5. Analysis by Sample Input
    • 6.2.6. Analysis by Type of Nucleic Acid Tested
    • 6.2.7. Analysis by Type of Cancer
    • 6.2.8. Analysis by Application Area
  • 6.3. Cancer Biomarkers Testing Solutions: Developer Landscape
    • 6.3.1. Analysis by Year of Establishment
    • 6.3.2. Analysis by Company Size
    • 6.3.3. Analysis by Location of Headquarters

7. PRODUCT COMPETITIVENESS ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Assumptions and Key Parameters
  • 7.3. Methodology
  • 7.4. Cancer Biomarkers Testing Solutions: Product Competitiveness Analysis
    • 7.4.1. Products Offered by Players Based in North America
    • 7.4.2. Products Offered by Players Based in Europe
    • 7.4.3. Products Offered by Players Based in Asia-Pacific

8. COMPANY PROFILES

  • 8.1. Chapter Overview
  • 8.2. Detailed Profiles of Leading Cancer Biomarker Testing Solutions Providers
    • 8.2.1. Agilent
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Financial Information
      • 8.2.1.3. Cancer Biomarker Testing Solutions Portfolio
      • 8.2.1.4. Recent Developments and Future Outlook
    • 8.2.2. ARUP Laboratories
      • 8.2.2.1. Company Overview
      • 8.2.2.2. Cancer Biomarker Testing Solutions Portfolio
      • 8.2.2.3. Recent Developments and Future Outlook
    • 8.2.3. BioReference
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Cancer Biomarker Testing Solutions Portfolio
      • 8.2.3.3. Recent Developments and Future Outlook
    • 8.2.4. Foundation Medicine
      • 8.2.4.1. Company Overview
      • 8.2.4.2. Cancer Biomarker Testing Solutions Portfolio
      • 8.2.4.3. Recent Developments and Future Outlook
    • 8.2.5. OncoDNA
      • 8.2.5.1. Company Overview
      • 8.2.5.2. Cancer Biomarker Testing Solutions Portfolio
      • 8.2.5.3. Recent Developments and Future Outlook
    • 8.2.6. Q2 Solutions
      • 8.2.6.1. Company Overview
      • 8.2.6.2. Cancer Biomarker Testing Solutions Portfolio
      • 8.2.6.3. Recent Developments and Future Outlook
    • 8.2.7. Thermo Fisher Scientific
      • 8.2.7.1. Company Overview
      • 8.2.7.2. Financial Information
      • 8.2.7.3. Cancer Biomarker Testing Solutions Portfolio
      • 8.2.7.4. Recent Developments and Future Outlook
    • 8.2.8. YuceBio
      • 8.2.8.1. Company Overview
      • 8.2.8.2. Cancer Biomarker Testing Solutions Portfolio
      • 8.2.8.3. Recent Developments and Future Outlook
  • 8.3. Short Profiles of Other Leading Cancer Biomarkers Testing Solutions Providers
    • 8.3.1. Asper Biogene
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Cancer Biomarker Testing Solutions Portfolio
    • 8.3.2. Caris Life Sciences
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Cancer Biomarkers Testing Solutions Portfolio
    • 8.3.3. CeGaT
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Cancer Biomarkers Testing Solutions Portfolio
    • 8.3.4. Genekor Medical
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Cancer Biomarkers Testing Solutions Portfolio
    • 8.3.5. Guardant Health
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Cancer Biomarker Testing Solutions Portfolio
    • 8.3.6. Labcorp
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Cancer Biomarker Testing Solutions Portfolio
    • 8.3.7. MedGenome
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Cancer Biomarker Testing Solutions Portfolio
    • 8.3.8. NeoGenomics Laboratories
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Cancer Biomarker Testing Solutions Portfolio
    • 8.3.9. Nonacus
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Cancer Biomarkers Testing Solutions Portfolio
    • 8.3.10. Oxford Gene Technology
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Cancer Biomarkers Testing Solutions Portfolio
    • 8.3.11. Personal Genome Diagnostics
      • 8.3.11.1. Company Overview
      • 8.3.18.3. Cancer Biomarkers Testing Solutions Portfolio
    • 8.3.12. PhenoPath
      • 8.3.12.1. Company Overview
      • 8.3.12.2. Cancer Biomarkers Testing Solutions Portfolio
    • 8.3.13. Positive Biosciences
      • 8.3.13.1. Company Overview
      • 8.3.13.2. Cancer Biomarkers Testing Solutions Portfolio
    • 8.3.14. Quest Diagnostics
      • 8.3.14.1. Company Overview
      • 8.3.14.2. Cancer Biomarkers Testing Solutions Portfolio
    • 8.3.15. Tempus
      • 8.3.15.1. Company Overview
      • 8.3.15.2. Cancer Biomarkers Testing Solutions Portfolio

9. INNOVATIVE STUDY DESIGNS FOR BIOMARKER-BASED CLINICAL TRIALS

  • 9.1. Chapter Overview
  • 9.2. Study Designs for Biomarker-based Clinical Trials
    • 9.2.1. Enrichment Design
    • 9.2.2. All-comers Design
    • 9.2.3. Mixture / Hybrid Design
    • 9.2.4. Adaptive Design
  • 9.3. Regulatory Guidelines for Biomarker-based Clinical Trial Designs

10. CLINICAL TRIAL ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Cancer Biomarkers: Clinical Trial Analysis
    • 10.3.1. Analysis by Trial Registration Year
    • 10.3.2. Analysis by Trial Status
    • 10.3.3. Analysis by Trial Registration Year and Trial Status
    • 10.3.4. Analysis by Trial Phase
    • 10.3.5. Analysis by Trial Registration Year and Trial Phase
    • 10.3.6. Analysis of Enrolled Patient Population by Trial Registration Year
    • 10.3.7. Analysis of Enrolled Patient Population by Trial Phase
    • 10.3.8. Analysis by Type of Sponsor / Collaborator
    • 10.3.9. Most Active Players: Distribution by Number of Registered Trials
    • 10.3.10. Analysis by Study Design
    • 10.3.11. Analysis by Type of Cancer
    • 10.3.12. Analysis of Clinical Trials by Geography
    • 10.3.13. Analysis of Clinical Trials by Trial Status and Geography
    • 10.3.14. Analysis of Enrolled Patient Population by Geography
    • 10.3.15. Analysis of Enrolled Patient Population by Trial Status and Geography

11. PUBLICATION ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Scope and Methodology
  • 11.3. Cancer Biomarkers: Publication Analysis
    • 11.3.1. Analysis by Year of Publication
    • 11.3.2. Analysis by Type of Publication
    • 11.3.3. Analysis by Type of Cancer
    • 11.3.4. Analysis by Copyright Holders
    • 11.3.5. Word Cloud: Emerging Focus Areas
    • 11.3.6. Most Active Publishers: Analysis by Number of Publications
    • 11.3.7. Key Journals: Analysis by Number of Publications
    • 11.3.8. Key Journals: Analysis by Impact Factor

12. BIG PHARMA PLAYERS: BENCHMARK ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Scope and Methodology
  • 12.3. Big Pharma Players: Benchmarking Analysis
    • 12.3.1. Spider Web Analysis: Abbott
    • 12.3.2. Spider Web Analysis: AbbVie
    • 12.3.3. Spider Web Analysis: Amgen
    • 12.3.4. Spider Web Analysis: AstraZeneca
    • 12.3.5. Spider Web Analysis: Bayer
    • 12.3.6. Spider Web Analysis: Boehringer Ingelheim
    • 12.3.7. Spider Web Analysis: Bristol-Myers Squib
    • 12.3.8. Spider Web Analysis: Eli Lilly
    • 12.3.9. Spider Web Analysis: Gilead
    • 12.3.10. Spider Web Analysis: GlaxoSmithKline
    • 12.3.11. Spider Web Analysis: Merck
    • 12.3.12. Spider Web Analysis: Novartis
    • 12.3.13. Spider Web Analysis: Pfizer
    • 12.3.14. Spider Web Analysis: Roche
    • 12.3.15. Spider Web Analysis: Sanofi
  • 12.4. Concluding Remarks

13. CASE STUDY: ANALYSIS OF VALUE CHAIN IN THE COMPANION DIAGNOSTICS INDUSTRY

  • 13.1. Chapter Overview
  • 13.2. Companion Diagnostics: Value Chain
  • 13.3. Cost Distribution Across the Value Chain
    • 13.3.1. Costs Associated with Research and Product Development
    • 13.3.2. Costs Associated with Manufacturing and Assembly
    • 13.3.3. Costs Associated with Clinical Trials, FDA Approval and Other Administrative Tasks
    • 13.3.4. Costs Associated with Payer Negotiation and KOL Engagement
    • 13.3.5. Costs Associated with Marketing and Sales

14. FUTURE GROWTH OPPORTUNITIES

  • 14.1. Chapter Overview
  • 14.2. Growing Focus on Personalized Medicines
  • 14.3. Extent of Biomarker Testing for Various Oncological Disorders
  • 14.4. Increase in Number of Biomarker-based Clinical Trials
  • 14.5. Increased Adoption of Emerging Analytical Techniques for Biomarker Assessment
  • 14.6. Development of Companion Diagnostic Products

15. GLOBAL CANCER BIOMARKERS MARKET

  • 15.1. Chapter Overview
  • 15.2. Assumptions and Methodology
  • 15.3. Global Cancer Biomarkers Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 15.3.1. Scenario Analysis
      • 15.3.1.1. Conservative Scenario
      • 15.3.1.2. Optimistic Scenario
  • 15.4. Key Market Segmentations

16. CANCER BIOMARKERS MARKET, BY TYPE OF BIOMARKER

  • 16.1. Chapter Overview
  • 16.2. Key Assumptions and Methodology
  • 16.3. Cancer Biomarkers Market: Distribution by Type of Biomarker, 2018, 2024 and 2035
    • 16.3.1. Cancer Biomarkers Market for HER2 Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 16.3.2. Cancer Biomarkers Market for MET Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 16.3.3. Cancer Biomarkers Market for EGFR Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 16.3.4. Cancer Biomarkers Market for PD-L1 Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 16.3.5. Cancer Biomarkers Market for NTRK Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 16.3.6. Cancer Biomarkers Market for ALK Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 16.3.7. Cancer Biomarkers Market for Other Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 16.3.7.1. Cancer Biomarkers Market: Distribution of Novel Biomarkers, 2018, 2024 and 2035
        • 16.3.7.1.1. Cancer Biomarkers Market for SNV Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
        • 16.3.7.1.2. Cancer Biomarkers Market for MSI Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
        • 16.3.7.1.3. Cancer Biomarkers Market for CNV Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
        • 16.3.7.1.4. Cancer Biomarkers Market for TMB Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
        • 16.3.7.1.5. Cancer Biomarkers Market for TIL Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 16.4. Data Triangulation and Validation

17. CANCER BIOMARKERS MARKET, BY TYPE OF CANCER

  • 17.1. Chapter Overview
  • 17.2. Key Assumptions and Methodology
  • 17.3. Cancer Biomarkers Market: Distribution by Type of Cancer, 2018, 2024 and 2035
    • 17.3.1. Cancer Biomarkers Market for Breast Cancer: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 17.3.2. Cancer Biomarkers Market for Prostate Cancer: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 17.3.3. Cancer Biomarkers Market for Colorectum Cancer: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 17.3.4. Cancer Biomarkers Market for Lung Cancer: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 17.3.5. Cancer Biomarkers Market for Thyroid Cancer: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 17.3.6. Cancer Biomarkers Market for Bladder Cancer: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 17.3.7. Cancer Biomarkers Market for Melanoma: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 17.3.8. Cancer Biomarkers Market for Non-Hodgkin Lymphoma: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 17.3.9. Cancer Biomarkers Market for Endometrial Cancer: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 17.3.10. Cancer Biomarkers Market for Kidney Cancer: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 17.3.11. Cancer Biomarkers Market for Leukemia: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 17.4. Data Triangulation and Validation

18. CANCER BIOMARKERS MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. Cancer Biomarkers Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
    • 18.3.1. Cancer Biomarkers Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 18.3.1.1. Cancer Biomarkers Market in the US: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 18.3.1.2. Cancer Biomarkers Market in Canada: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 18.3.2. Cancer Biomarkers Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 18.3.2.1. Cancer Biomarkers Market in the UK: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 18.3.2.2. Cancer Biomarkers Market in Germany: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 18.3.2.3. Cancer Biomarkers Market in France: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 18.3.2.4. Cancer Biomarkers Market in Spain: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 18.3.2.5. Cancer Biomarkers Market in Italy: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 18.3.3. Cancer Biomarkers Market in Aisa-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 18.3.3.1. Cancer Biomarkers Market in China: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 18.3.3.2. Cancer Biomarkers Market in Japan: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 18.3.3.3. Cancer Biomarkers Market in India: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 18.3.3.4. Cancer Biomarkers Market in Australia: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 18.3.3.2. Cancer Biomarkers Market in South Korea: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 18.3.3.2. Cancer Biomarkers Market in New Zealand: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 18.3.4. Cancer Biomarkers Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 18.3.4.1. Cancer Biomarkers Market in Brazil: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 18.3.4.2. Cancer Biomarkers Market in Argentina: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 18.3.4.3. Cancer Biomarkers Market in Chile: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 18.3.4.4. Cancer Biomarkers Market in Egypt: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 18.4. Data Triangulation and Validation

19. CONCLUDING REMARKS

20. EXECUTIVE INSIGHTS

  • 20.1. Chapter Overview
  • 20.2. Cell IDc
    • 20.2.1. Company Snapshot
    • 20.2.2. Interview Transcript: David Schwartz, Chief Technical Officer and Helen Synder, Former Director of Preclinical Development & Strategic Partnerships
  • 20.3. CeGat
    • 20.3.1. Company Snapshot
    • 20.3.2. Interview Transcript: Kirill Shur, Business Manager
  • 20.4. NeoGenomics Laboratories
    • 20.4.1. Company Snapshot
    • 20.4.2. Interview Transcript: Lawrence Weiss, Former Chief Scientific Officer

21. APPENDIX 1: TABULATED DATA

22. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS